About KPV Source

What KPV Source Is

KPV Source is a sourcebook: a place where the peer-reviewed work on KPV — the C-terminal tripeptide of alpha-MSH — is summarized in plain language and traced back to where it came from. The "Source" in the name is exactly that, a source of the published record, not a source of the compound. Nothing here is a service. The site treats no one, prescribes nothing, and offers no medical advice; it neither makes, holds, nor ships any product. Its single job is to report what the studies measured and to show its work, identifier by identifier.

The "Source" in our name means a source of the published research record — a place to read what the studies actually measured, cited to the primary literature. It is not a storefront, and nothing here is offered for sale, dispensed, or supplied. KPV is a research chemical sold by chemical suppliers for laboratory use only ^[20]; this site documents the science, not a supply channel.

How We Handle the Literature

We read KPV as a tight, vivid deck of preclinical findings and present it straight. Every quantitative claim on the site — a concentration, a model, an outcome figure like 8 of 8 rabbit corneas re-epithelialized by 60 hours ^[6] — maps to a numbered citation. Where the evidence is preclinical, we say so. Where there is no human data, we say that too: no published human clinical trial of KPV exists ^[16].

Secondary web sources for KPV are unusually prone to PMID and DOI errors, so we re-verified every identifier against PubMed and Crossref and cite the FDA's own pages for regulatory facts. The domain modifier — "Source" — is editorial framing for the position this publisher occupies relative to the literature. It is not a claim that the site provides products, treatment, consultation, or prescriptions.

KPV is a molecule with a witty signature: derived from the pigment hormone alpha-MSH, it keeps the calm and sheds the color. We chose a glowing-poster register to match that, and held it to editorial discipline so the honest caveats — preclinical only, peptidase-labile, research-only — are never undercut by the design.

We also try to be clear about what the modifier in our name does not mean. "KPV Source" describes a source of the published literature, the position this publisher takes relative to the science. It is not a clinic, a pharmacy, or a supply channel, and reading it as one would misread the project. Where the FDA record is relevant — for example, that KPV is named on a scheduled compounding-advisory agenda but is not an approved drug — we state the present-tense fact and cite the FDA page, and we do not assert any future regulatory outcome as settled ^[16].